Clinical Trials Logo

Urothelial Carcinoma Ureter clinical trials

View clinical trials related to Urothelial Carcinoma Ureter.

Filter by:
  • None
  • Page 1

NCT ID: NCT06120387 Recruiting - Locally Advanced Clinical Trials

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Start date: November 10, 2023
Phase:
Study type: Observational

In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.

NCT ID: NCT05979909 Not yet recruiting - Clinical trials for Urothelial Carcinoma Ureter

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Start date: September 2023
Phase: Phase 1
Study type: Interventional

The objective of this pilot study is to determine the feasibility of conducting a phase III randomized trial of intravesical mitomycin C (MMC) for prevention of intravesical recurrence (IVR) after diagnostic ureteroscopy for suspected upper tract urothelial carcinoma (UTUC). In the current study, 40 patients will be randomized to receive MMC or no intervention and will be followed for two years to determine the incidence of adverse events and IVR.

NCT ID: NCT05874921 Recruiting - Clinical trials for Urothelial Carcinoma

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

uTRACT
Start date: November 17, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

NCT ID: NCT05494411 Available - Clinical trials for Urothelial Carcinoma

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Start date: n/a
Phase:
Study type: Expanded Access

This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

NCT ID: NCT04865939 Recruiting - Clinical trials for Urothelial Carcinoma Ureter

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Start date: November 29, 2021
Phase: Phase 3
Study type: Interventional

There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical irrigation with sterile water has equivalent efficacy to intravesical chemotherapy in prevention of recurrent bladder cancer following transurethral resection of bladder tumors (TURBT). This study is intended to compare recurrence rates using intravesical gemcitabine (as a pseudo-standard of care) and continuous bladder irrigation with sterile water.

NCT ID: NCT03606174 Terminated - Clinical trials for Urothelial Carcinoma

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Start date: September 11, 2018
Phase: Phase 2
Study type: Interventional

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.